Skip to main content
Clinical Trials/NCT02645669
NCT02645669CompletedPhase 2

Effect of a Locally Delivered Probiotic as an Adjunct To Scaling And Root Planing In The Management Of Chronic Periodontitis

SVS Institute of Dental Sciences1 site in 1 country30 target enrollmentStarted: February 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
In vitro Estimation of S. boulardii viability

Study Overview

Brief Summary

Saccharomyces boulardii is commonly employed as a live non-pathogenic probiotic microbial feed or food supplement. S. boulardii reduces the secretion of key pro inflammatory cytokines and promotes the production of anti-inflammatory cytokines such as IL-10, which is pertinent in the context of pathogenic mechanisms in periodontitis.

Detailed Description

One method of altering the subgingival environment is by using probiotics. Probiotics are live microorganisms, which when administered in adequate amounts, confer a health benefit on the host by passively occupying a niche that may otherwise be colonized by pathogens. This tends to limit a pathogen's ability to bind to tissue surfaces and to produce virulence factors.8 In the past few years, probiotics have been investigated for periodontal health. Studies have shown that certain gut bacteria can exert beneficial effects in the oral cavity by inhibiting pathogenic species. Teughels et al., in a study showed that application of beneficial oral bacteria subgingivally after scaling and root planing led to a more host compatible subgingival microbiota which may also effect the promotion of a beneficial host response.10 Studies have revealed that probiotic Lactobacillus strains (L. reuteri, L salivarius, L. casei, L. acidophilus) were useful in reducing gingival inflammation and the number of black-pigmented rods, including Porphyromonas gingivalis, in the saliva and subgingival plaque. Streptococcus sanguinis & S. uberis were found to inhibit the growth of periodontopathogens & a strong negative between Aggregatibacter actinomycetemcomitans and S. sanguinis. Weissella cibaria isolates in the form of probiotic rinse possess the ability to inhibit biofilm formation, both in vitro and in vivo.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
25 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subjects having at least one pocket ≥5 mm in each quadrant were included in the study.

Exclusion Criteria

  • •Medically compromised patients and patients having received any form of surgical or non-surgical therapy in the 6 month period leading to the study were not included.

Arms & Interventions

Study site

Experimental

Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture

Intervention: Study site (Procedure)

Control site

Placebo Comparator

Only Scaling and Root planing (SRP) was performed

Intervention: Control site (Procedure)

Outcomes

Primary Outcomes

In vitro Estimation of S. boulardii viability

Time Frame: up to 14 days

S boulardii-FOS mixture was stored for 3 weeks at 25ºC for periodic analysis (upto14 days) of microorganism viability on a selective medium. Briefly, the mixture was plated on Sabouraud's agar plates at 30°C and colony forming units (CFU) were enumerated after 24 to 48 h of incubation. Colonies were expressed as total log count per mg of sample (log10 CFU/mg).

Viability of the probiotic mixture in the periodontal pocket

Time Frame: up to 7 days

Viable cell count was determined by serial dilution method on Emmons' modification of Sabouraud's agar medium and colonies were expressed as total log count per ml of sample (log10 CFU/ml). Only colonies that were opaque, light brown, smooth and 2-3 mm in diameter were counted.

Secondary Outcomes

  • GI(up to 6 months)
  • PI(up to 6 months)
  • PPD(up to 6 months)
  • CAL(up to 6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr R Viswa Chandra

Professor and Head, Periodontics, SVSIDS, Mahabubnagar

SVS Institute of Dental Sciences

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 3
Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea. Randomised, double-blind, placebo-controlled trialantibiotic-associated diarrhoeaA04.7Enterocolitis due to Clostridium difficile
DRKS00000084Bernhard-Nocht-Institut für Tropenmedizin477
Active, not recruiting
Not Applicable
Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoeaAntibiotic - associated - Diarrhoea (AAD)Clostridium difficile - associated - Diarrhoea (CDAD)MedDRA version: 14.1Level: LLTClassification code 10012748Term: Diarrhoea, Clostridium difficileSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10006835Term: C.difficile diarrhoeaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10055956Term: Antibiotic-associated diarrhoeaSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2009-017374-20-DEBernhard-Nocht-Institute for Tropical Medicine1,520
Recruiting
Not Applicable
The effect of yeast probiotic (saccharomyces boulardii) on acute diarrhea in childreAcute diarrhea.Shigellosis
IRCT2017090812897N3Qazvin University of Medical Sciences60
Completed
Not Applicable
Probiotics and Examination-related Stress in Healthy Medical StudentsAnxietyHealthyStress-related Problem
NCT03427515Medical University of Lodz92
Recruiting
Phase 3
Probiotic saccharomyces boulardi in knee osteoarthritisKnee osteoarthritis.Osteoarthritis, unspecified siteM19.9
IRCT20161022030424N4Tabriz University of Medical Sciences70